

Supplementary Table 2. Odds ratios for the hepatic steatosis stages according to u-NCR in insulin non-user ($n=249$)

Model	Hepatic steatosis stage 1 (S1)		Hepatic steatosis stage 2 (S2)		Hepatic steatosis stage 3 (S3)	
	aOR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value	aOR (95% CI)	<i>P</i> value
1	1.65 (0.86–3.14)	0.132	0.97 (0.55–1.72)	0.910	0.86 (0.46–1.61)	0.631
2	1.72 (0.89–3.31)	0.110	0.98 (0.53–1.80)	0.944	0.87 (0.45–1.65)	0.661
3	1.81 (0.88–3.73)	0.111	1.09 (0.57–2.07)	0.801	0.71 (0.34–1.45)	0.340
4	1.77 (0.84–3.73)	0.133	0.63 (0.29–1.37)	0.242	0.52 (0.22–1.19)	0.120

Model 1 was adjusted for age, male sex, body mass index, and duration of diabetes; Model 2 adjusted for model 1 parameters plus hypertension, lipid medication; Model 3 adjusted for Model 2 parameters plus triglyceride, alanine aminotransferase, homeostasis model assessment of insulin resistance; Model 4 adjusted for Model 3 parameters plus glycosylated hemoglobin, homeostasis model assessment- β . u-NCR, urinary *N*-acetyl- β -D-glucosaminidase to creatinine ratio; aOR, adjusted odds ratio; CI, confidence interval.